ANIP ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.
Company profile
Ticker
ANIP
Exchange
Website
CEO
Patrick Walsh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BEN ABRAHAM TECHNOLOGIES INC, BIOSANTE PHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
582301143
ANIP stock data
()
News
ANI Pharmaceuticals Acquires New Drug Applications For OXISTAT Lotion, VEREGEN Ointment And Pandel Cream And Abbreviated NDA For ApexiCon E Cream
6 Apr 21
The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data
9 Mar 21
ANI Pharmaceuticals Q4 Adj. EPS $0.80 Misses $0.94 Estimate, Sales $57.30M Beat $54.27M Estimate
9 Mar 21
ANI Pharmaceuticals To Acquire Novitium Pharma For $163.5M
9 Mar 21
Earnings Scheduled For March 9, 2021
9 Mar 21
Press releases
ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs
6 Apr 21
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth
9 Mar 21
ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business
9 Mar 21
ANI Pharmaceuticals, Inc. to Host Earnings Call
9 Mar 21
ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Feb 21
Calendar
11 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.87M | 12.87M | 12.87M | 12.87M | 12.87M | 12.87M |
Cash burn (monthly) | 3.35M | 4.54M | 794K | 1.94M | 1.9M | (positive/no burn) |
Cash used (since last report) | 11.49M | 15.6M | 2.73M | 6.65M | 6.54M | n/a |
Cash remaining | 1.38M | -2.73M | 10.14M | 6.22M | 6.33M | n/a |
Runway (months of cash) | 0.4 | -0.6 | 12.8 | 3.2 | 3.3 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Apr 21 | Carey Stephen P. | Common Stock | Payment of exercise | Dispose F | No | No | 33.69 | 612 | 20.62K | 115,542 |
6 Apr 21 | Marken James G. | Common Stock | Payment of exercise | Dispose F | No | No | 33.69 | 337 | 11.35K | 116,199 |
31 Mar 21 | Carey Stephen P. | Common Stock | Payment of exercise | Dispose F | No | No | 36.14 | 508 | 18.36K | 116,154 |
31 Mar 21 | Marken James G. | Common Stock | Payment of exercise | Dispose F | No | No | 36.14 | 278 | 10.05K | 116,536 |
29 Mar 21 | Schrepfer Robert W | Common Stock | Payment of exercise | Dispose F | No | No | 32.68 | 5,566 | 181.9K | 87,477 |
29 Mar 21 | Carey Stephen P. | Common Stock | Payment of exercise | Dispose F | No | No | 32.68 | 953 | 31.14K | 116,662 |
29 Mar 21 | Marken James G. | Common Stock | Payment of exercise | Dispose F | No | No | 32.68 | 524 | 17.12K | 116,814 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|
Financial report summary
?Competition
Sun Pharmaceutical Industries • Evoke Pharma • Perrigo • Mylan II B.V. • Amneal PharmaceuticalsManagement Discussion
- In July 2020, we acquired an ANDA and certain related inventories from a private company for total consideration of $4.3 million. The transaction was funded using cash on hand.
- In May 2020, we entered into an agreement with a private company to purchase an ANDA and API for one currently marketed generic drug product and certain API for $0.2 million. The transaction was funded using cash on hand.
- In January 2020, we completed the acquisition of the U.S. portfolio of 23 generic products and API and finished goods related to certain of those products from Amerigen Pharmaceuticals, Ltd. ("Amerigen") for a purchase consideration of $56.8 million and up to $25.0 million in contingent payments over the next three years. The product portfolio at the time of the acquisition included ten commercial products, three approved products with launches pending, four filed products and four in-development products as well as a license to commercialize two approved products. The transaction was funded using cash on hand and $15.0 million in borrowings under our $75.0 million Revolver.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accrual, agree, agreed, al, Ampersand, Amphetamine, anniversary, anticompetitive, antitrust, appointed, area, argument, Aspartate, assignee, augment, aware, Azar, Baltimore, BBA, Bexarotene, bidding, Biden, biopharmaceutical, Biotech, biotechnology, Bipartisan, Bird, Blueprint, Boehringer, boomer, Budget, built, bulk, burgeoning, Bystolic, Cabaret, CDMO, CEO, Chad, Chali, Citrate, Colorado, colorectal, compliant, composition, Congressional, consequential, constitutionality, contact, counter, creative, defect, departed, Department, departure, Dextroamphetamine, diminish, disagreement, disgorgement, distancing, distracted, domain, downstream, Dr, easing, economy, elapsed, empowered, encompassing, encourage, encouraged, Eq, Eshhar, Esjay, Europe, European, explore, Ezetimibe, feasible, Florida, footprint, Forest, frame, fringe, Gassert, gastrointestinal, Gilead, goal, grew, GTM, guideline, heard, heightened, Hetero, HHS, Hightower, incentivize, induce, inducement, Ingelheim, inorganic, instance, Israeli, Jeanne, joined, Judge, judicial, kidney, Kite, Koepsel, Kroger, Lalwani, led, length, lengthy, Lineberry, liver, Lovette, Master, MD, MDL, medicinal, Memantine, mEq, Mexico, Mexiletine, Miglustat, mission, Monohydrate, month, MPIC, multidistrict, Muthusamy, NaN, negligence, negligent, NEO, Nikhil, Nile, Novitium, nuisance, onboarding, oncology, outbreak, outpatient, Paliperidone, pandemic, Paragraph, pendency, Penicillamine, perspective, Pfizer, PIPE, placement, plaintiff, pocket, Potassium, premise, Presidential, programmatic, prominent, province, purposeful, quantified, quarantine, reached, recalculated, recalculating, recycling, regional, reinstituted, remand, repaid, replead, resubmission, resume, reuse, reward, Robin, Rosenberg, RTF, Saccharate, salary, sanitation, scrutiny, sensitivity, Shanmugam, shift, Simvastatin, situation, sNDA, sound, Southern, sparsely, SPI, spread, staggered, static, stomach, Sulfamethoxazole, territory, Thoma, Thorappadi, timeline, Tolterodine, Torrent, trailing, training, transparency, travel, treble, Trimethoprim, Tripartite, turnover, unbilled, undisclosed, undue, University, unprecedented, unreasonable, Vijayaraj, visited, voluntarily, waived, Walgreen, Watson, widespread, withholding, world, worsen, worsening, Zantac, Zelig
Removed:
absorbed, activator, acute, adjunct, adjunctive, adjuvant, adult, advancing, agent, allegedly, alpha, amortizing, analog, androgen, angina, angiotensin, annualization, annualized, antagonist, antihypertensive, anxiety, APIC, Apo, appetite, aromatase, arrhythmia, ascending, ascribed, assigned, Atropine, Australia, back, backlog, batch, bipolar, blocker, blood, boom, bowel, brain, breast, bringing, capsule, carcinoma, cardiovascular, castration, cautionary, chronic, collectability, collection, concomitantly, congestive, consecutive, construed, continuity, conventional, cough, counterparty, cream, curb, daytime, decreasing, deducting, define, diabetic, diarrhea, diet, Diphenoxylate, discounted, discrete, disorder, distal, diuretic, documented, dyslipidemia, earlier, elevated, embedded, emerge, entirety, Etodolac, exceeding, exhaustive, extinguishment, fatal, feeling, Flecainide, fluctuated, fluid, formal, front, funding, gastric, gastroesophageal, glaucoma, Gulfport, headache, heal, heart, heartbeat, heartburn, hemorrhage, historic, Holmdel, hypercholesterolemia, hypertension, hypertriglyceridemia, hypertrophic, IDT, implied, incidence, inclusion, incurrence, Indapamide, indenture, indexed, inflammatory, inhibitor, inInternal, intensity, interfere, intermediate, intraocular, irregular, ischemic, leasing, Louisiana, lowering, LP, luteinizing, Maleate, manic, meal, measurable, Media, met, metastatic, migraine, mild, Mississippi, myocardial, nausea, negotiate, neurological, Nilutamide, Nimodipine, nonfatal, NYHA, object, occupationally, ocular, Orange, Overlay, oxycodone, pain, Pennsylvania, percent, peroxisome, Pindolol, pose, postmenopausal, preceding, preoperatively, privately, proliferator, Propafenone, proportion, propriety, proscribed, prostate, proved, pruritic, putting, receptor, rectal, recurrent, reflux, reimbursable, reintroduce, renamed, reorganization, replaced, represented, repurchased, revaluation, revise, rheumatoid, rule, ruptured, salt, satisfaction, seasonal, seasonality, secondary, simultaneously, socially, stroke, subaortic, subarachnoid, supplementary, surgery, surgical, swelling, symptomatic, synthetically, systematically, TG, theInternal, tolerance, transverse, treat, ulcerative, underwriting, unpaid, Unregistered, unwinding, update, vomiting, warrant, writing, yielding
Financial reports
10-K
2020 FY
Annual report
11 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
Current reports
8-K
ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs
6 Apr 21
8-K
ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business
9 Mar 21
8-K
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth
9 Mar 21
8-K
Departure of Directors or Certain Officers
17 Feb 21
8-K
ANI Pharmaceuticals Reports Third Quarter 2020 Results
5 Nov 20
8-K
ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio “Tony” Pera to Board of Directors
6 Aug 20
8-K
ANI Pharmaceuticals Reports Second Quarter 2020 Results
6 Aug 20
8-K
ANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer
3 Aug 20
8-K
Submission of Matters to a Vote of Security Holders
11 Jun 20
8-K
ANI Pharmaceuticals Provides Update on Recent Regulatory Filing
1 Jun 20
Registration and prospectus
S-8
Registration of securities for employees
23 Nov 20
S-3
Shelf registration
9 Jul 20
S-3
Shelf registration
11 Jun 17
S-8
Registration of securities for employees
18 May 17
S-8
Registration of securities for employees
2 Nov 16
POS AM
Prospectus update (post-effective amendment)
19 Feb 15
424B5
Prospectus supplement for primary offering
7 Dec 14
FWP
Free writing prospectus
4 Dec 14
424B5
Prospectus supplement for primary offering
3 Dec 14
S-8
Registration of securities for employees
3 Jun 14
Proxies
DEFA14A
Additional proxy soliciting materials
9 Mar 21
DEFA14A
Additional proxy soliciting materials
9 Mar 21
DEFA14A
Additional proxy soliciting materials
21 May 20
DEFA14A
Additional proxy soliciting materials
30 Apr 20
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
23 Apr 20
DEFA14A
Additional proxy soliciting materials
4 Apr 19
DEF 14A
Definitive proxy
4 Apr 19
DEF 14A
Definitive proxy
5 Apr 18
DEF 14A
Definitive proxy
5 Apr 17
Other
EFFECT
Notice of effectiveness
20 Jul 20
CORRESP
Correspondence with SEC
15 Jul 20
UPLOAD
Letter from SEC
13 Jul 20
CT ORDER
Confidential treatment order
15 May 20
CT ORDER
Confidential treatment order
13 Apr 20
CT ORDER
Confidential treatment order
2 Apr 20
CT ORDER
Confidential treatment order
1 Apr 20
CT ORDER
Confidential treatment order
1 Jul 19
CT ORDER
Confidential treatment order
18 Mar 19
CT ORDER
Confidential treatment order
22 Feb 19
Ownership
4
ANI PHARMACEUTICALS / James G. Marken ownership change
7 Apr 21
4
ANI PHARMACEUTICALS / STEPHEN P. CAREY ownership change
7 Apr 21
4
ANI PHARMACEUTICALS / James G. Marken ownership change
31 Mar 21
4
ANI PHARMACEUTICALS / STEPHEN P. CAREY ownership change
31 Mar 21
4
ANI PHARMACEUTICALS / Robert W Schrepfer ownership change
29 Mar 21
4
ANI PHARMACEUTICALS / James G. Marken ownership change
25 Mar 21
4
ANI PHARMACEUTICALS / STEPHEN P. CAREY ownership change
25 Mar 21
4
ANI PHARMACEUTICALS / Nikhil Lalwani ownership change
25 Mar 21
4
ANI PHARMACEUTICALS / THOMAS HAUGHEY ownership change
25 Mar 21
4
ANI PHARMACEUTICALS / Robert E. Brown JR ownership change
25 Mar 21
Transcripts
2020 Q4
Earnings call transcript
9 Mar 21
2020 Q3
Earnings call transcript
8 Nov 20
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
9 Aug 20
2020 Q1
Earnings call transcript
9 May 20
2019 Q4
Earnings call transcript
27 Feb 20
2019 Q2
Earnings call transcript
7 Aug 19
2019 Q1
Earnings call transcript
9 May 19
2018 Q4
Earnings call transcript
27 Feb 19
2018 Q3
Earnings call transcript
6 Nov 18